A larger test of the prevention claim
A 2024 UK primary-care trial randomized 598 adult women with recurrent urinary tract infections to approximately 2 g of D-mannose powder daily or a matched fructose placebo for six months. Participants and relevant study staff were blinded. The trial tested prevention of further medically attended suspected infections, not treatment of an active infection. [1]
What the numbers showed
Primary-outcome data were available for 583 women. A further suspected UTI leading to a care contact occurred in 150 of 294 participants receiving D-mannose (51.0%) and 161 of 289 receiving placebo (55.7%). The reported risk difference was −5 percentage points, with a 95% confidence interval from −13 to +3. The trial did not establish a preventive benefit. [1]
Why the lower percentage is not enough
The uncertainty interval includes no difference and results favoring either group. Reading only the two percentages would leave that uncertainty out. Conversely, the result is not proof that every imaginable preparation has precisely zero effect; it is evidence against recommending the tested approach on the basis of a demonstrated benefit in this population.
Notice the denominator. The headline enrollment was 598, while the primary-outcome calculation used the 583 participants with available outcome data. Keeping those numbers distinct makes it possible to reproduce the reported percentages rather than accidentally dividing by the wrong group sizes.
| Claim or observation | What can be concluded | What cannot be assumed |
|---|---|---|
| The treatment percentage is lower | An observed numerical difference | A proven benefit without uncertainty analysis |
| A study measures future episodes | A prevention question | Treatment of a current infection |
| A confidence interval crosses zero | No difference remains compatible | Precise proof of zero effect |
How far can the result be applied?
The primary outcome did not require culture confirmation for every episode. Adherence and scoop consistency were limitations. Pregnant or lactating women and catheter users were excluded. NIHR funded the study; authors reported no conflicts and no funder role in its conduct or reporting. [1]
An active infection needs a different decision
NIDDK explains that bacterial bladder infections are generally treated with antibiotics selected by a clinician. Some urinary symptoms have other causes, so a supplement should not be used to bypass assessment. Take prescribed treatment as directed and discuss side effects rather than changing the plan yourself. [2]
When prompt care matters
Fever or chills, back or side pain, painful urination, nausea or vomiting can accompany a kidney infection. NIDDK advises seeking care right away for kidney-infection symptoms. Do not wait to see whether D-mannose helps before seeking that care. [3]
A prevention plan can still move forward
If recurrent symptoms are affecting daily life, bring the pattern of episodes and previous test results to a clinician. Ask which prevention options fit the established diagnosis and your circumstances. This trial gives a reason to question a routine D-mannose purchase; it does not imply that nothing can be done about recurrent infections.
Sources for this article
- Hayward et al. — D-mannose for recurrent UTI prevention, randomized trial (2024)
Source consulted: 2026-09-17. This is a reference resource, not a claim that we conducted the studies or tested a product. - NIDDK — Treatment for bladder infection in adults
Source consulted: 2026-09-17. This is a reference resource, not a claim that we conducted the studies or tested a product. - NIDDK — Symptoms and causes of kidney infection
Source consulted: 2026-09-17. This is a reference resource, not a claim that we conducted the studies or tested a product.